Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | January 21, 2015

Key Late-breaking Trials to Watch at ACC.15

The America College of Cardiology has released its list of key late-breaking clinical trials at the ACC 2015 meeting in March. Here are my top picks for cardiovascular device technology I am looking forward to hearing data on: 

1. Perhaps the key trial at ACC will be data from the large BEST study, which compares the Xience V drug-eluting stent (DES) to coronary bypass grft (CABG) surgery in patients with multivessel disease. It is a follow up to the SYNTAX trial, which fell short in showing the Taxus DES (at the time the top-performing stent) had long-term durability compared to CABG. However, Abbott's Xience second-generation DES beat out Taxus in the SPRIRT IV trial a couple years ago. Intervascular imaging and FFR today also see more expanded use, which combined with an improved stent platform, is expected to tip the scale in favor of stenting. 

2. More data will be presented, likely further supporting the use of transcatheter aortic valve replacement (TAVR). This includes long-term outcomes from the Edwards Sapien and Medtronic Corevalve trials, and first experience with use of a TAVR embolic protection system. The most important of the trial presentations might be data from an all-comers trial of TAVR verses surgery. This data could help open the flood gates for TAVR as a standard therapy to replace open heart procedures.
 
3. Use of CT angiography to evaluate patients presenting with chest pain to reduce costs. There a a few CTA trials being presented, which I suspect will add more evidence that CTA can be used as a primary rule-out test to help eliminate series blood testing, nuclear scans, stress tests and diagnostic angiograms.
 
4. Denervation to treat pulmonary hypertension. Renal denervation trials have had very mixed results, but experts still say the denervation may hold promise for other therapeutic areas such as this one.
 
5. Initial experience and outcomes with the MitraClip mital valve leaflet repair system. I believe this is just the beginning of a whole new segment of interventional mitral valve repair therapies that will eventually replace open heart mitral procedures.
 
6. There are two trials comparing transradial access, which is a growing trend in the United States to help lower access site complications. One will compare transradial to transfemoral access sites, and another radial verses ulnar access. 
 
See the complete list of late breaking trials, presentation locations and times. 

Below is a preview of some technologies being shown on the expo floor.

 

Related Content

Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient to treat heart failure..

Navin Kapur, M.D., Tufts Medical Center, shows preCardia device and its anatomical positioning in the patient.

News | Heart Failure | June 23, 2020
June 23, 2020 — The U.S.
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio
News | Heart Failure | March 29, 2020
March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational
Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis. #ACC20 #ACC2020
News | Heart Failure | March 28, 2020
March 28, 2020 — New data from a sub-analysis of the landmark Phase III...
News | Heart Failure | March 05, 2020
March 5, 2020 — Abbott recently received Breakthrough Device designation from the U.S.
Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA. #heartfailure

Some of the new devices technologies to treat heart failure that are either in clinical trials or were recently cleared by the U.S. FDA. 

Feature | Heart Failure | February 21, 2020 | Dave Fornell, Editor
There are several new tools being added to the clinical armamentarium in the fight against...
Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced care, as show here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. The operator is Nevin Kapur. Photo by Dave Fornell.

Tufts Medical Center created a heart failure team approach to care for its patients. The program includes an interventional heart failure fellowship program, where interventional cardiologists learn more advanced hemodynamic support methods, as shown here with an ECMO procedure being performed in a cath lab at Tufts. The interventional cardiologists learn how to better care for heart failure patients and interface with surgeons, intensivists and others on the HF care team. Photo by Dave Fornell.

Feature | Heart Failure | February 20, 2020 | Dave Fornell, Editor
There is no, single magic bullet in heart failure (HF) to easily reduce readmission rates or easily reverse this...
he U.S. Food and Drug Administration (FDA) has approved Carmat's investigational device exemption (IDE) application to start a U.S. early feasibility study (EFS) of its total artificial heart.
News | Heart Failure | February 12, 2020
February 12, 2020 — The U.S.